Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Vaxart ( (VXRT) ) is now available.
On September 2, 2025, Vaxart announced the retirement of Michael J. Finney, Ph.D., from its Board of Directors, effective September 30, 2025. Dr. Finney’s departure, due to personal reasons, led to a reduction in the board size from six to five members. His leadership and contributions were acknowledged as pivotal to Vaxart’s growth and mission. The board plans to meet to discuss future leadership and governance, aiming to continue advancing the company’s scientific progress.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall score is primarily influenced by its strong revenue growth and promising vaccine developments, which are offset by significant profitability challenges and technical bearishness. The negative P/E ratio and NASDAQ listing issues further weigh on the stock’s attractiveness.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. These vaccines, designed to be administered in pill form, can be stored and shipped without refrigeration, reducing the risk of needle-stick injuries. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV), marking its first venture into immune-oncology.
Average Trading Volume: 4,578,788
Technical Sentiment Signal: Sell
Current Market Cap: $89.28M
See more insights into VXRT stock on TipRanks’ Stock Analysis page.